Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.

被引：1
|
作者：
Lumish, Melissa Amy [1 ]
Maron, Steven Brad [1 ]
Paroder, Viktoriya [1 ]
Philemond, Steven [1 ]
Donoghue, Joseph A. O' [1 ]
Schoder, Heiko [1 ]
Lewis, Jason Stuart [1 ]
Janjigian, Yelena Y. [1 ]
Pandit-Taskar, Neeta [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4068
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
    Janjigian, Yelena Y.
    Viola-Villegas, Nerissa
    Holland, Jason P.
    Divilov, Vadim
    Carlin, Sean D.
    Gomes-DaGama, Erica M.
    Chiosis, Gabriela
    Carbonetti, Gregory
    de Stanchina, Elisa
    Lewis, Jason S.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (06) : 936 - 943
  • [2] Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
    Dijkers, E. C.
    Munnink, T. H. Oude
    Kosterink, J. G.
    Brouwers, A. H.
    Jager, P. L.
    de Jong, J. R.
    van Dongen, G. A.
    Schroder, C. P.
    Lub-de Hooge, M. N.
    de Vries, E. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (05) : 586 - 592
  • [3] PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).
    Gebhart, Geraldine
    Lamberts, Laetitia E.
    Garcia, Camilo
    Ameye, Lieveke
    Stroobants, Sigrid
    Huizing, Manon
    Aftimos, Philippe G.
    Tol, Jolien
    Oyen, Wim J. G.
    Wimana, Zena
    van Dongen, G. A. M. S.
    Hoekstra, Otto S.
    Schroder, Carolien P.
    Gaye, Julie
    Menke, Catharina Wilhelmina
    Guiot, Thomas
    Brouwers, Adrienne H.
    Awada, Ahmad
    de Vries, Elisabeth G. E.
    Flamen, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] HER-2-PET imaging with 89Zr-trastuzumab in metastatic breast cancer patients
    Munnink, T. Oude
    Dijkers, E.
    Hooge, M. Lub-de
    Kosterink, J.
    Brouwers, A.
    de Jong, J.
    van Dongen, G.
    de Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] 18F-FDG, 18F-4FMFES, and 89Zr-trastuzumab PET imaging protocol in a preclinical breast cancer model
    Paquette, Michel
    Beaudoin, Simon
    Phoenix, Serge
    Fafard-Couture, Laurent
    Lecomte, Roger
    Guerin, Brigitte
    Turcotte, Aric
    Leyton, Jeff
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [6] Clinical value of 89Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
    Schroder, C. P.
    Bensch, F.
    Brouwers, A. H.
    Lub-de Hooge, M. N.
    de Jong, J. R.
    van der Vegt, B.
    Sleijfer, S.
    de Vries, E. G.
    CANCER RESEARCH, 2017, 77
  • [7] Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo
    Janjigian, Y. Y.
    Villegas, N. T.
    Holland, J. P.
    Shah, M. A.
    Divilov, V.
    Kelsen, D. P.
    Lewis, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [8] Cancer screening with 18F-FDG PET.
    Ide, M
    Nakai, K
    Takahashi, W
    Suzuki, T
    Fujii, H
    Matsuyama, S
    Yasuda, S
    Suzuki, Y
    Shohtsu, A
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 309P - 309P
  • [9] Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
    Ulaner, Gary A.
    Hyman, David M.
    Ross, Dara S.
    Corben, Adriana
    Chandarlapaty, Sarat
    Goldfarb, Shari
    McArthur, Heather
    Erinjeri, Joseph P.
    Solomon, Stephen B.
    Kolb, Hartmuth
    Lyashchenko, Serge K.
    Lewis, Jason S.
    Carrasquillo, Jorge A.
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (10) : 1523 - 1528
  • [10] Human dosimetry of 89Zr-trastuzumab-PET in patients with HER2-positive breast cancer
    Laforest, Richard
    Lapi, Suzanne
    Bose, Ron
    Tabchy, Adel
    Oyama, Reiko
    Marquez, Bernadette
    Burkemper, Jennifer
    Wright, Brian
    Siegel, Barry
    Dehdashti, Farrokh
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
12345